InMed Pharmaceuticals Inc
INM0.940USD
-0.041-4.21%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
2.45M시가총액
0.02P/E TTM
자세한 내용은 InMed Pharmaceuticals Inc 회사
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc 정보
종목 코드 INM
회사 이름InMed Pharmaceuticals Inc
상장일Jun 21, 2001
CEOAdams (Eric A)
직원 수- -
유형Ordinary Share
회계 연도 종료Jun 21
주소1445-885 West Georgia St.
도시VANCOUVER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호V6C 3E8
전화16046697207
웹사이트https://www.inmedpharma.com/
종목 코드 INM
상장일Jun 21, 2001
CEOAdams (Eric A)
InMed Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-425.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
Sabby Management, LLC
9.99%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
기타
84.54%
주주
주주
비율
Sabby Management, LLC
9.99%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
기타
84.54%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
12.86%
Investment Advisor
1.29%
Research Firm
0.74%
Hedge Fund
0.60%
Individual Investor
0.15%
기타
84.37%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
29
434.23K
15.48%
+143.86K
2025Q3
30
135.23K
4.82%
+48.77K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Sabby Management, LLC
220.00K
7.85%
+183.86K
+508.82%
Sep 30, 2025
Yorkville Advisors Global, LP.
80.37K
2.87%
+80.37K
--
Dec 13, 2024
DRW Securities, LLC
35.87K
1.28%
+35.87K
--
Sep 30, 2025
Virtu Americas LLC
20.37K
0.73%
+20.37K
--
Sep 30, 2025
Renaissance Technologies LLC
16.80K
0.6%
+16.80K
--
Sep 30, 2025
Adams (Eric Ashley)
2.20K
0.08%
--
--
Oct 22, 2025
Hull (Andrew Harold)
1.91K
0.07%
--
--
Oct 22, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Sep 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
날짜
배당락일
유형
비율
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
